Home » Stocks » VNRX

VolitionRX Limited (VNRX)

Stock Price: $3.06 USD -0.01 (-0.33%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 161.85M
Revenue (ttm) 38,419
Net Income (ttm) -20.62M
Shares Out 52.89M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $3.06
Previous Close $3.07
Change ($) -0.01
Change (%) -0.33%
Day's Open 3.06
Day's Range 3.00 - 3.08
Day's Volume 78,166
52-Week Range 2.85 - 6.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to hel...

2 days ago - PRNewsWire

Secured strongest-ever balance sheet with approximately $33.1 million in cash Strengthened the Company's leadership team to drive commercial focus Expanded the Company's intellectual property portfolio ...

2 months ago - PRNewsWire

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday May 12, at 8:00 a.m. Eastern time to discuss ...

2 months ago - PRNewsWire

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...

3 months ago - PRNewsWire

AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...

3 months ago - PRNewsWire

AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...

3 months ago - PRNewsWire

Launched first product, the Nu.Q® Vet Cancer Screening Test and recorded first revenue from sales of a commercial product Engaged Diagnostic Oncology CRO LLC to conduct U.S. regulatory clinical trial fo...

4 months ago - PRNewsWire

AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...

4 months ago - PRNewsWire

AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to disc...

4 months ago - PRNewsWire

AUSTIN, Texas, March 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer, Cameron Reynolds, and its Executive Vice President, I...

4 months ago - PRNewsWire

Volition is one of the sponsors for the upcoming Benzinga Global Small Cap Conference set to take place on December 8-9, 2020. Given the growing population, it is expected that the number of cancer diag...

7 months ago - Benzinga

VolitionRx began commercial sales of a blood test for pet cancer. There is no other product available on the market for testing cancer in dogs despite cancer being the leading cause of death for dogs ov...

7 months ago - Seeking Alpha

DOUGLAS, Isle of Man--(BUSINESS WIRE)--Cotterford Co. Ltd. (“Cotterford”) the beneficial owner of approximately 26% of the outstanding shares of VolitionRX Limited (“Volition”) (AMEX: VNRX), today sent ...

1 year ago - Business Wire

VolitionRx (VNRX) Investor Presentation - Slideshow

1 year ago - Seeking Alpha

VolitionRx Limited's (VNRX) CEO Cameron Reynolds on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

These healthcare stocks are all worth a "buy" now. The healthcare sector will keep chugging along despite market volatility.

Other stocks mentioned: CATS, ENSG, FLGT, JYNT, NEO, VIEMF
1 year ago - InvestorPlace

VolitionRX Limited (VNRX) CEO Cameron Reynolds on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

VolitionRX Ltd. (VNRX) CEO Cameron Reynolds on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About VNRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.

Industry
Diagnostics & Research
Stock Exchange
NYSEAMERICAN
Ticker Symbol
VNRX
Full Company Profile

Financial Performance

In 2020, VolitionRX's revenue was $13,433, a decrease of -21.43% compared to the previous year's $17,096. Losses were -$20.35 million, 26.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for VolitionRX stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 161.44% from the latest price.

Price Target
$8.00
(161.44% upside)
Analyst Consensus: Strong Buy